# An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis

> **NCT00383188** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 305 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** placebo
- **DRUG:** PH-797804
- **DRUG:** PH-797804
- **DRUG:** PH-797804
- **DRUG:** PH-797804

## Key facts

- **NCT ID:** NCT00383188
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-15
- **Primary completion:** 2008-07-01
- **Final completion:** 2008-07-16
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383188, "An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00383188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*